ImmunoPET imaging of LAG-3 expression in tumor microenvironment with 68 Ga-labelled cyclic peptides tracers: from bench to bedside.

Background: Lymphocyte activation gene 3 (LAG-3) has been considered as the next generation of immune checkpoint and a promising prognostic biomarker of immunotherapy. As with programmed cell death protein-1/programmed death-ligand 1 and cytotoxic T-lymphocyte antigen-4 inhibitors, positron emission tomography (PET) imaging strategies could benefit the development of clinical decision-making of LAG-3-related therapy. In this study, we developed and validated ⁶⁸ Ga-labeled cyclic peptides tracers for PET imaging of LAG-3 expression in bench-to-bedside studies.
Methods: A series of LAG-3-targeted cyclic peptides were modified and radiolabeled with ⁶⁸ GaCl ₃ and evaluated their affinity and specificity, biodistribution, pharmacokinetics, and radiation dosimetry in vitro and in vivo. Furthermore, hu-PBL-SCID (PBL) mice models were constructed to validate the capacity of [ ⁶⁸ Ga]Ga-CC09-1 for mapping of LAG-3 ⁺ lymphocytes infiltrates using longitudinal PET imaging. Lastly, [ ⁶⁸ Ga]Ga-CC09-1 was translated into the first-in-human studies to assess its safety, biodistribution and potential for imaging of LAG-3 expression.
Results: A series of cyclic peptides targeting LAG-3 were employed as lead compounds to design and develop ⁶⁸ Ga-labeled PET tracers. In vitro binding assays showed higher affinity and specificity of [ ⁶⁸ Ga]Ga-CC09-1 in Chinese hamster ovary-human LAG-3 cells and peripheral blood mononuclear cells. In vivo PET imaging demonstrated better imaging capacity of [ ⁶⁸ Ga]Ga-CC09-1 with a higher tumor uptake of 1.35±0.33 per cent injected dose per gram and tumor-to-muscle ratio of 17.18±3.20 at 60 min post-injection. Furthermore, [ ⁶⁸ Ga]Ga-CC09-1 could detect the LAG-3 ⁺ lymphocyte infiltrates in spleen, lung and salivary gland of PBL mice. In patients with melanoma and non-small cell lung cancer, primary lesions with modest tumor uptake were observed in [ ⁶⁸ Ga]Ga-CC09-1 PET, as compared with that of [ ¹⁸ F]FDG PET. More importantly, [ ⁶⁸ Ga]Ga-CC09-1 delineated the heterogeneity of LAG-3 expression within large tumors.
Conclusion: These findings consolidated that [ ⁶⁸ Ga]Ga-CC09-1 is a promising PET tracer for quantifying the LAG-3 expression in tumor microenvironment, indicating its potential as a companion diagnostic for patients stratification and therapeutic response monitoring in anti-LAG-3 therapy.
Competing Interests: Competing interests: None declared.
(© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)